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Abstract 
A patient with extensive and painful chest wall involvement from a metastatic borderline 
cancer of the ovary was treated with a carboplatin plus paclitaxel chemotherapy 
regimen. She achieved a rather dramatic improvement of pain control, a significant 
biochemical response with 75% reduction of the CA-125 antigen level, but only limited 
radiographic tumor regression. This experience emphasizes the potential clinical utility 
of platinum-based cytotoxic chemotherapy in the setting of symptomatic advanced 
borderline ovarian cancer. 
 
Epithelial ovarian cancer is among the most chemotherapy sensitive solid tumors with 
anticipated major objective response rates of 70–80% to several primary platinum-based 
combination chemotherapy regimens [1]. Even in the setting of recurrent disease, patients 
who have not received chemotherapy for more than 18 to 24 months may be anticipated 
to achieve partial remission rates of more than 60% following reintroduction of this class 
of cytotoxic drugs [2–4]. Further, available data document the biological and clinical 
activity of a number of non-platinum-based strategies in both the recurrent and 
platinum-resistant settings, as well as the favorable impact of such treatment on overall 
survival [5–8]. 
However, for one group of epithelial ovarian malignancies there remains uncertainty 
regarding the benefits associated with the administration of cytotoxic anti-neoplastic 
agents, including the platinum drugs. 
Most borderline ovarian cancers present at an early stage where surgical treatment 
alone is curative in the large majority of cases [9–11]. However, this malignancy can 
progress in a manner essentially identical to that observed with the higher-grade epithelial  
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cancers involving this organ, despite the fact that patients with this condition generally 
exhibit a far more indolent natural history even when initially presenting at an advanced 
stage [10–13]. 
Although limited evidence to the contrary exists [14], considerable published literature 
has questioned the clinical utility associated with the administration of chemotherapy to 
women with borderline ovarian cancers [14–16]. The essential argument is that the 
anticipated very low objective response rate and uncertain impact of anti-neoplastic drug 
treatment on survival leads to the suggestion that patients are unlikely to benefit from 
cytotoxic chemotherapy [14–16]. These conclusions are supported by data demonstrating 
the quite modest activity of current chemotherapy in low-grade serous ovarian cancer 
[17]. 
A recently managed patient with extensive chest wall involvement from a metastatic 
borderline ovarian tumor challenges this negative perspective, at least as regards the 
potential favorable impact of cytotoxic chemotherapy in the provision of symptomatic 
relief and substantially influencing overall clinical management. 
Case History 
The patient, a 39-year-old female, was diagnosed with a right-sided ‘large cystic tumor’ in 1994, and 
treated with a unilateral salpingo-oophorectomy. (Note: Review of the pathology from this surgery was 
not available.) A left-sided salpingo-oophorectomy was performed in 2004, which revealed a borderline 
serous papillary tumor. The histologic diagnosis was reviewed and confirmed by a nationally recognized 
gynecologic pathologist. 
Recently, the patient developed a palpable and painful posterior chest wall mass over a period of 
several months. A core biopsy confirmed similar histology to the previously documented borderline 
ovarian cancer. A CT scan showed a large, multi-lobular, infiltrating mass (>10 cm) with involvement of 
the chest wall muscles and adjacent rib. Following discussions with the patient and several consultant 
physicians, a surgical resection was entertained and neo-adjuvant chemotherapy was recommended to 
debulk the tumor mass prior to local therapy (surgery and/or external beam radiation). 
After the first cycle of carboplatin and paclitaxel chemotherapy, the local pain was largely resolved. 
After the second cycle, the discrete mass was no longer palpable by physical examination, although the 
ill-defined localized fullness persisted. The serum CA-125 antigen level has consecutively decreased 
from 306 prior to chemotherapy to 86 after the fourth cycle. The CT scan after the fourth cycle showed 
less than 25% reduction in the measurable size of the tumor. The patient tolerated chemotherapy well, 
with a grade 1 sensory neuropathy after the third cycle, and remained free of pain medication after the 
second cycle. The patient was very encouraged psychologically and physiologically by the pain relief. 
The current plan is to complete six cycles of chemotherapy, followed by a surgical resection, and 
adjuvant external beam radiation to achieve an optimal local control. 
Discussion 
Previously reported data have identified the relatively long natural history associated 
with the diagnosis of an advanced borderline tumor of the ovary [10–13]. While it has 
been shown that cytotoxic chemotherapy may produce objective tumor regressions [14, 
15], the impact of treatment on a responding patient’s ultimate outcome is uncertain. 
In the patient reported here, cytotoxic chemotherapy was employed both to achieve 
relief of painful symptoms and to facilitate an optimal local management. It is important 
to acknowledge that it is unknown whether a subjective and biochemical response will 
translate into a favorable impact on overall survival. However, the case emphasizes that  
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combination chemotherapy can provide significant improvement in cancer-associated 
symptoms in advanced borderline tumor of the ovary.  
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